THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. – Trademark Portfolio

Entity Type: 99

THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. Currently, 1 trademark is registered. Notable registered marks include THOUSAND OAKS. The owner is based in NANTONG, JIANGSU.

BUILDING B1, HAIMEN BIOTECH AND

NANTONG, JIANGSU 226133 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. have?

THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. file in?

THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 42 (Computer & Scientific). Class 42 covers scientific and technological services; industrial analysis and research services.

What are THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD.'s most well-known trademarks?

THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD.'s registered trademark portfolio includes well-known marks such as THOUSAND OAKS. These are among 1 currently registered trademark in the portfolio.

What is THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD.'s trademark registration success rate?

THOUSAND OAKS BIOPHARMA (NANTONG) CO., LTD. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.